SCNN1A has been reported to be the direct transcriptional target of the oncogene achaete-scute homolog 1, which can be pharmacologically targeted with antitumor effects in neuroendocrine cancer cells [55]. This evidence concerns the gene SCNN1A and neuroendocrine carcinoma.